Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jaad.2025.08.053 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Outcomes of Spesolimab Treatment of Generalized Pustular Psoriasis and Psoriasis with Pustules for 12 Weeks: A Prospective Cohort Study from China.
J Am Acad Dermatol
August 2025
Department of Dermatology, Xiangya Hospital, Central South University, Changsha, China; National Engineering Research Center of Personalized Diagnostic and Therapeutic Technology, Changsha, China; Furong Laboratory, Changsha, China; National Clinical Research Center for Geriatric Disorders, Xiangya
Spesolimab Treatment in GPP: Impact of IL-36RN Mutations and Concomitant Plaque Psoriasis.
Clin Cosmet Investig Dermatol
August 2025
Department of Dermatology, Guangzhou Dermatology Hospital, Guangzhou, 510095, People's Republic of China.
We present a case series involving five patients with generalized pustular psoriasis (GPP) who received a single intravenous dose of 900 mg spesolimab in our department from September 2023 to January 2024. Spesolimab was effective in three patients, regardless of their IL-36RN gene mutation status. Two patients with concomitant plaque psoriasis, despite initially poor responses to spesolimab, achieved resolution of pustules after switching their therapy to ixekizumab or secukinumab.
View Article and Find Full Text PDFAchieving Therapeutic Success with Spesolimab: Two Cases of Drug-Induced Generalized Pustular Psoriasis Initially Mimicking Acute Generalized Exanthematous Pustulosis.
J Inflamm Res
July 2025
Department of Dermatology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China.
Background: Patients with newly diagnosed generalized pustular psoriasis (GPP) lacking a history of psoriasis but with recent medication exposure may present with clinical features overlapping with acute generalized exanthematous pustulosis (AGEP). Accurate differentiation is critical for treatment and prognosis.
Case Summary: We report two cases of drug-induced GPP initially with AGEP-like manifestations.
Treatment with spesolimab in patients with generalized pustular psoriasis: a review of real-world experience.
Clin Exp Dermatol
August 2025
Department of Rheumatology, University Hospital 'Dr. José Eleuterio González', Universidad Autonoma de Nuevo Leon, Monterrey, Mexico.
Generalized pustular psoriasis (GPP) is a potentially life-threatening rare immune-mediated disease characterized by rapid onset of erythematous plaques, sterile pustules and systemic inflammation. Spesolimab, a monoclonal antibody targeting the interleukin-36 receptor, is a novel treatment for GPP. However, GPP's low incidence and limited evidence relating to treatment with spesolimab represents a challenge in determining its real-world efficacy.
View Article and Find Full Text PDF